A smart insulin device under development could revolutionize how glucose levels are monitored in diabetes patients and deliver insulin doses when necessary.
Sanofi and Abbott are partnering to integrate glucose sensing and insulin delivery technologies that would help to further simplify how people with diabetes manage their condition.
A new discovery at the Feinstein Institutes for Medical Research could have implications in the way diabetes is treated in the future.
For a while now there has been a heated debate surrounding hybrid and closed loop insulin systems.
A European Medicines Agency (EMA) panel recommended granting marketing approval to the diabetes drug Steglatro developed by Merck & Co. Inc. and Pfizer Inc.
Digital devices designed to monitor the wearer’s health in much greater detail than current models will need regulatory approval, and Apple Inc., Fitbit Inc. and seven other companies will take part in a program to speed the approval process, the U.S. health regulator said.
Lexicon Pharmaceuticals Inc. announced additional positive data from the pivotal Phase 3 inTandem2 study of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor.
The European Union’s top court barred Germany’s Dextro Energy from making claims about the health benefits of glucose contained in its products, which include Dextrose tablets.
Protein-Packed Breakfast Prevents Body Fat Gain In Overweight Teens High-protein breakfast also improves teens’ glycemic control Approximately 60 percent of young people habitually skip breakfast up to four times a week, previous research has shown. Although health experts recommend breakfast as a strategy to reduce an individual’s chance of obesity, little research has examined if […]